Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Biofrontera ( (BFRI) ) has issued an update.
On December 31, 2025, Biofrontera Inc., a Delaware corporation listed on the Nasdaq Capital Market, was notified by Nasdaq that its common stock had fallen out of compliance with the exchange’s minimum bid price requirement after trading below $1.00 for 34 consecutive business days. While the notice does not immediately affect the trading or listing of the shares, the company has until June 30, 2026, to lift its closing bid price to at least $1.00 for 10 consecutive business days or potentially secure an additional compliance period, failing which it could face delisting, appeal processes, or the need for measures such as a reverse stock split as it seeks to preserve its Nasdaq listing and reassure stakeholders about ongoing compliance risks.
The most recent analyst rating on (BFRI) stock is a Hold with a $0.79 price target. To see the full list of analyst forecasts on Biofrontera stock, see the BFRI Stock Forecast page.
Spark’s Take on BFRI Stock
According to Spark, TipRanks’ AI Analyst, BFRI is a Neutral.
The score is held down primarily by weak financial performance—persistent losses, ongoing cash burn, and negative equity. Offsetting this somewhat are a mixed-but-improving strategic outlook from the latest earnings call (rights acquisition and actions aimed at breakeven in FY2026) and generally neutral technical conditions, while valuation provides limited support due to negative earnings and no dividend yield.
To see Spark’s full report on BFRI stock, click here.
More about Biofrontera
Average Trading Volume: 234,131
Technical Sentiment Signal: Sell
Current Market Cap: $9.28M
For detailed information about BFRI stock, go to TipRanks’ Stock Analysis page.